Literature DB >> 22029468

Gamma Knife® radiosurgery for trigeminal neuralgia.

Chun-Po Yen1, David Schlesinger, Jason P Sheehan.   

Abstract

Trigeminal neuralgia is characterized by a temporary paroxysmal lancinating facial pain in the trigeminal nerve distribution. The prevalence is four to five per 100,000. Local pressure on nerve fibers from vascular loops results in painful afferent discharge from an injured segment of the fifth cranial nerve. Microvascular decompression addresses the underlying pathophysiology of the disease, making this treatment the gold standard for medically refractory trigeminal neuralgia. In patients who cannot tolerate a surgical procedure, those in whom a vascular etiology cannot be identified, or those unwilling to undergo an open surgery, stereotactic radiosurgery is an appropriate alternative. The majority of patients with typical facial pain will achieve relief following radiosurgical treatment. Long-term follow-up for recurrence as well as for radiation-induced complications is required in all patients undergoing stereotactic radiosurgery for trigeminal neuralgia.

Entities:  

Mesh:

Year:  2011        PMID: 22029468     DOI: 10.1586/erd.11.46

Source DB:  PubMed          Journal:  Expert Rev Med Devices        ISSN: 1743-4440            Impact factor:   3.166


  3 in total

1.  Comparative analysis between 5 mm and 7.5 mm collimators in CyberKnife radiosurgery for trigeminal neuralgia.

Authors:  H Sudahar; P G G Kurup; V Murali; J Velmurugan
Journal:  J Med Phys       Date:  2013-07

2.  Trigeminal neuralgia treatment outcomes following Gamma Knife radiosurgery with a minimum 3-year follow-up.

Authors:  Sana D Karam; Alexander Tai; Margaux Wooster; Abdul Rashid; Rosanna Chen; Nimrah Baig; Ann Jay; K William Harter; Pamela Randolph-Jackson; Adedamola Omogbehin; Edward F Aulisi; Jeff Jacobson
Journal:  J Radiat Oncol       Date:  2013-11-20

3.  Refractory trigeminal neuralgia treatment outcomes following CyberKnife radiosurgery.

Authors:  Sana D Karam; Alexander Tai; James W Snider; Shilpa Bhatia; Edward J Bedrick; Abdul Rashid; Ann Jay; Christopher Kalhorn; Nathan Nair; K William Harter; Sean P Collins; Walter Jean
Journal:  Radiat Oncol       Date:  2014-12-14       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.